Free Trial
NYSEARCA:PBE

Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News

$63.97
-1.06 (-1.63%)
(As of 05/23/2024 ET)
Today's Range
$63.77
$65.09
50-Day Range
$59.62
$65.44
52-Week Range
$52.47
$67.76
Volume
7,251 shs
Average Volume
13,125 shs
Market Capitalization
$258.44 million
Assets Under Management
$260.88 million
Dividend Yield
0.06%
Net Expense Ratio
0.58%
PBE stock logo

About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund’s investment adviser.

PBE Stock Price History

PBE ETF News Headlines

See More Headlines
Receive PBE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Invesco
Fund Name
Invesco Biotechnology & Genome ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:PBE
Inception Date
6/23/2005
Fund Manager
Peter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser

Fund Focus

Asset Class
Equity
Benchmark
Dynamic Biotech & Genome Intellidex Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
31

Fund Statistics

Assets Under Management
$260.88 million
Average Daily Volume
$16,975.90
Discount/Premium
-0.03%

Administrator, Advisor and Custodian

Administrator
The Bank of New York Mellon Corporation
Advisor
Invesco Capital Management LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
Invesco Distributors, Inc.
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Citadel

Options

Optionable
N/A
Short Interest
9,000 shs

Miscellaneous

Beta
0.88
Creation Unit
10,000
Creation Fee
$500.00
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Invesco Biotechnology & Genome ETF Expenses

TypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.50%0.56%0.54%0.51%0.51%
Other Expenses0.08%0.40%0.54%0.64%0.58%
Total Expense0.58%0.72%0.70%0.74%0.70%
Fee Waiver0.00%-0.53%-0.54%-0.68%-0.56%
Net Expense0.58%0.60%0.60%0.58%0.58%

Invesco Biotechnology & Genome ETF (PBE) Holdings & Exposure


PBE ETF - Frequently Asked Questions

How have PBE shares performed in 2024?

Invesco Biotechnology & Genome ETF's stock was trading at $65.84 on January 1st, 2024. Since then, PBE stock has decreased by 2.8% and is now trading at $63.97.
View the best growth stocks for 2024 here
.

What does PBE invest in?

Invesco Biotechnology & Genome ETF is a equity fund issued by Invesco. PBE focuses on health care investments and follows the Dynamic Biotech & Genome Intellidex Index. The fund's investments total to approximately $260.88 million assets under management.

What stocks does Invesco Biotechnology & Genome ETF hold?
What is the management fee for Invesco Biotechnology & Genome ETF?

Invesco Biotechnology & Genome ETF's management fee is 0.50% and has other expenses of 0.08%. The net expense ratio for PBE is 0.58%.

What other stocks do shareholders of Invesco Biotechnology & Genome ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Biotechnology & Genome ETF investors own include Pfizer (PFE), Intel (INTC), Align Technology (ALGN), Micron Technology (MU), Activision Blizzard (ATVI), DocuSign (DOCU), Inovio Pharmaceuticals (INO), Mastercard (MA), Hello Group (MOMO) and ONEOK (OKE).

Who are Invesco Biotechnology & Genome ETF's major shareholders?

Invesco Biotechnology & Genome ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include CreativeOne Wealth LLC (1.06%), YHB Investment Advisors Inc. (0.65%), Raymond James Financial Services Advisors Inc. (0.50%), US Bancorp DE (0.44%), Massachusetts Wealth Management (0.39%) and Commonwealth Equity Services LLC (0.37%).

How do I buy shares of Invesco Biotechnology & Genome ETF?

Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:PBE) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners